Phase 3 Migraine Trial, Recruiting NCT07496034 Sponsor: Tsai, Chueh-Yi, MD Condition: Migraine
Back to Migraine

Phase 3 Migraine Trial, Recruiting

NCT07496034
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old.
  • You have had migraines on and off (not constant) for at least 12 months before the screening period, diagnosed according to standard medical guidelines or by a doctor.
  • During the 28-day screening period, you experienced headaches on at least 6 but no more than 14 days, with at least 4 of those days being migraine days (confirmed through a headache diary).
  • You are either not currently taking any medication to prevent migraines, or you are taking no more than one such medication at a steady dose for at least 2 months before joining.
  • Your body weight is between 35 kg (about 77 lbs) and 120 kg (about 265 lbs), and your body mass index (a measure of weight relative to height) is between 17.5 and 37.5.
  • You completed a headache diary on at least 24 out of 28 days during the screening period.
  • You are able to follow the study rules and complete all required steps in the trial.
  • You are able to understand and sign the consent form agreeing to participate.
  • You do not have any serious heart, liver, or kidney disease.

Who may not be able to join:

  • You have a known allergy or sensitivity to Gou-Teng-San (the herbal medicine being studied) or any of its ingredients.
  • You received Botox (botulinum toxin type A) injections in your head, face, or neck for any reason within the past 4 months.
  • You use medications containing opioids or barbiturates (certain types of strong painkillers or sedatives) on more than 4 days per month.
  • You have already tried at least 2 types of standard migraine prevention medications for 3 or more months each without success (confirm with trial site).
  • You had a procedure such as a nerve block or transcranial magnetic stimulation (a brain stimulation treatment) to treat migraines within the past 2 months.
  • You have a significant ongoing medical condition — such as a serious heart, lung, kidney, liver, neurological, or psychiatric problem — that the doctor running the trial believes could interfere with your participation.
  • You have taken part in another clinical trial of a drug or medical device within the past 2 months, or within a certain time period related to that trial's medication (whichever is longer).
  • You have used any other Chinese herbal medicines within the past 4 weeks.
  • You have previously been treated with a specific class of newer migraine medications known as CGRP-targeting therapies (confirm with trial site).
  • You have had a problem with alcohol or drug misuse within the past 2 years.
  • You are currently breastfeeding, are pregnant, or are unwilling to use contraception during the study if you are able to become pregnant.
  • The doctor running the trial has another reason to believe you would not be a good fit or would be unlikely to complete the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886-4-2473-9595

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tsai, Chueh-Yi, MD
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change from Baseline in Mean Monthly Migraine Days at 4 Weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov